Julian Harrison
Stock Analyst at BTIG
(4.29)
# 456
Out of 5,133 analysts
81
Total ratings
57.53%
Success rate
15.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LQDA Liquidia | Reiterates: Buy | $49 | $38.09 | +28.64% | 6 | Jan 13, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $63 → $73 | $31.34 | +132.93% | 4 | Jan 12, 2026 | |
| MLTX MoonLake Immunotherapeutics | Upgrades: Buy | $24 | $17.10 | +40.35% | 3 | Jan 9, 2026 | |
| ARDX Ardelyx | Maintains: Buy | $14 → $17 | $7.04 | +141.48% | 1 | Jan 9, 2026 | |
| ABVX ABIVAX Société Anonyme | Maintains: Buy | $120 → $150 | $119.64 | +25.38% | 4 | Jan 8, 2026 | |
| RZLT Rezolute | Reiterates: Buy | $5 | $2.48 | +101.61% | 5 | Jan 8, 2026 | |
| APGE Apogee Therapeutics | Maintains: Buy | $128 → $137 | $79.00 | +73.42% | 4 | Jan 6, 2026 | |
| MREO Mereo BioPharma Group | Maintains: Buy | $6 → $1 | $0.66 | +51.52% | 2 | Dec 29, 2025 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $100 → $118 | $36.58 | +222.58% | 2 | Dec 16, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $5 | $1.38 | +262.32% | 3 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $40 | $20.33 | +96.75% | 3 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $38 | $10.73 | +254.15% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $44 | $7.66 | +474.41% | 2 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.18 | +358.72% | 2 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 | $31.99 | +90.68% | 4 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $82 | $81.36 | +0.79% | 3 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $4.13 | +93.70% | 3 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $15 | $4.56 | +228.95% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $13.80 | +102.90% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $17.20 | +132.56% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $31.53 | +122.01% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $41.39 | -10.61% | 3 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $19.50 | - | 3 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $48.13 | - | 2 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $9 | $0.56 | +1,503.14% | 5 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $2.71 | +195.20% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.57 | +1,314.93% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.74 | +20,061.29% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $476.86 | - | 2 | Feb 11, 2022 |
Liquidia
Jan 13, 2026
Reiterates: Buy
Price Target: $49
Current: $38.09
Upside: +28.64%
Oruka Therapeutics
Jan 12, 2026
Maintains: Buy
Price Target: $63 → $73
Current: $31.34
Upside: +132.93%
MoonLake Immunotherapeutics
Jan 9, 2026
Upgrades: Buy
Price Target: $24
Current: $17.10
Upside: +40.35%
Ardelyx
Jan 9, 2026
Maintains: Buy
Price Target: $14 → $17
Current: $7.04
Upside: +141.48%
ABIVAX Société Anonyme
Jan 8, 2026
Maintains: Buy
Price Target: $120 → $150
Current: $119.64
Upside: +25.38%
Rezolute
Jan 8, 2026
Reiterates: Buy
Price Target: $5
Current: $2.48
Upside: +101.61%
Apogee Therapeutics
Jan 6, 2026
Maintains: Buy
Price Target: $128 → $137
Current: $79.00
Upside: +73.42%
Mereo BioPharma Group
Dec 29, 2025
Maintains: Buy
Price Target: $6 → $1
Current: $0.66
Upside: +51.52%
Nektar Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $100 → $118
Current: $36.58
Upside: +222.58%
Akebia Therapeutics
Dec 2, 2025
Reiterates: Buy
Price Target: $5
Current: $1.38
Upside: +262.32%
Nov 26, 2025
Maintains: Buy
Price Target: $25 → $40
Current: $20.33
Upside: +96.75%
Nov 24, 2025
Maintains: Buy
Price Target: $32 → $38
Current: $10.73
Upside: +254.15%
Nov 14, 2025
Maintains: Buy
Price Target: $42 → $44
Current: $7.66
Upside: +474.41%
Nov 13, 2025
Reiterates: Buy
Price Target: $10
Current: $2.18
Upside: +358.72%
Nov 4, 2025
Reiterates: Buy
Price Target: $61
Current: $31.99
Upside: +90.68%
Oct 28, 2025
Reiterates: Buy
Price Target: $82
Current: $81.36
Upside: +0.79%
Oct 16, 2025
Reiterates: Buy
Price Target: $8
Current: $4.13
Upside: +93.70%
Oct 13, 2025
Maintains: Buy
Price Target: $55 → $15
Current: $4.56
Upside: +228.95%
Oct 9, 2025
Initiates: Buy
Price Target: $28
Current: $13.80
Upside: +102.90%
Sep 29, 2025
Reiterates: Buy
Price Target: $40
Current: $17.20
Upside: +132.56%
Sep 16, 2025
Reiterates: Buy
Price Target: $70
Current: $31.53
Upside: +122.01%
Sep 12, 2025
Maintains: Buy
Price Target: $30 → $37
Current: $41.39
Upside: -10.61%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $19.50
Upside: -
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $48.13
Upside: -
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $0.56
Upside: +1,503.14%
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $2.71
Upside: +195.20%
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.57
Upside: +1,314.93%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.74
Upside: +20,061.29%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $476.86
Upside: -